Cara Therapeutics Future Growth
Future criteria checks 2/6
Cara Therapeutics is forecast to grow earnings and revenue by 37.3% and 46.4% per annum respectively while EPS is expected to grow by 53.1% per annum.
Key information
37.3%
Earnings growth rate
53.1%
EPS growth rate
| Pharmaceuticals earnings growth | 21.6% |
| Revenue growth rate | 46.4% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 11 Nov 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 7 | -37 | N/A | -36 | 3 |
| 12/31/2025 | 6 | -46 | N/A | -52 | 3 |
| 12/31/2024 | 7 | -74 | N/A | -63 | 3 |
| 9/30/2024 | 9 | -96 | -77 | -74 | N/A |
| 6/30/2024 | 11 | -111 | -83 | -80 | N/A |
| 3/31/2024 | 17 | -123 | -91 | -88 | N/A |
| 12/31/2023 | 21 | -119 | -94 | -92 | N/A |
| 9/30/2023 | 21 | -117 | -99 | -98 | N/A |
| 6/30/2023 | 27 | -112 | -104 | -104 | N/A |
| 3/31/2023 | 43 | -84 | -88 | -88 | N/A |
| 12/31/2022 | 42 | -85 | -79 | -79 | N/A |
| 9/30/2022 | 39 | -89 | -57 | -56 | N/A |
| 6/30/2022 | 49 | -66 | -45 | -45 | N/A |
| 3/31/2022 | 26 | -93 | -62 | -62 | N/A |
| 12/31/2021 | 23 | -88 | -60 | -60 | N/A |
| 9/30/2021 | 134 | 24 | 23 | 23 | N/A |
| 6/30/2021 | 123 | 8 | 15 | 16 | N/A |
| 3/31/2021 | 129 | 14 | 9 | 9 | N/A |
| 12/31/2020 | 135 | 8 | -6 | -5 | N/A |
| 9/30/2020 | 28 | -99 | -119 | -119 | N/A |
| 6/30/2020 | 24 | -115 | -123 | -123 | N/A |
| 3/31/2020 | 24 | -113 | -120 | -120 | N/A |
| 12/31/2019 | 20 | -106 | -109 | -109 | N/A |
| 9/30/2019 | 21 | -98 | -102 | -102 | N/A |
| 6/30/2019 | 20 | -85 | -97 | -97 | N/A |
| 3/31/2019 | 18 | -79 | -31 | -31 | N/A |
| 12/31/2018 | 13 | -74 | -22 | -22 | N/A |
| 9/30/2018 | 8 | -68 | -9 | -9 | N/A |
| 6/30/2018 | 3 | -61 | N/A | 1 | N/A |
| 3/31/2018 | N/A | -53 | N/A | -52 | N/A |
| 12/31/2017 | 1 | -58 | N/A | -55 | N/A |
| 9/30/2017 | 1 | -66 | N/A | -57 | N/A |
| 6/30/2017 | 1 | -65 | N/A | -60 | N/A |
| 3/31/2017 | 1 | -69 | N/A | -59 | N/A |
| 12/31/2016 | 0 | -57 | N/A | -47 | N/A |
| 9/30/2016 | 0 | -45 | N/A | -38 | N/A |
| 6/30/2016 | 3 | -38 | N/A | -33 | N/A |
| 3/31/2016 | 3 | -31 | N/A | -26 | N/A |
| 12/31/2015 | 4 | -25 | N/A | -21 | N/A |
| 9/30/2015 | 5 | -19 | N/A | -23 | N/A |
| 6/30/2015 | 3 | -21 | N/A | -20 | N/A |
| 3/31/2015 | 3 | -19 | N/A | -20 | N/A |
| 12/31/2014 | 3 | -18 | N/A | -18 | N/A |
| 9/30/2014 | 3 | -16 | N/A | -17 | N/A |
| 6/30/2014 | 3 | -14 | N/A | -16 | N/A |
| 3/31/2014 | 12 | -6 | N/A | 2 | N/A |
| 12/31/2013 | 12 | -3 | N/A | 3 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 69C is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 69C is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 69C is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 69C's revenue (46.4% per year) is forecast to grow faster than the German market (5.6% per year).
High Growth Revenue: 69C's revenue (46.4% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 69C's Return on Equity is forecast to be high in 3 years time